Urologic cancer drugs

Companies developing drugs to treat bladder, kidney and prostate cancer.
+6.4%
over 6 months · S&P 500 +2.6%

Key indicators

Health
51 / 100
Fragile
Solid
Up over 1 year
8 of 12
Volatility
65%
Calm
Choppy
Profitability
−244%
Low
High
Health and price: against the other tags.